Gilead Sciences, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Erin Burkhart, SVP, Controllership of Gilead Sciences, Inc., reported multiple transactions in common stock on September 22, 2026.
NASDAQ
Form 4: Gilead Sciences CFO Sells Shares
Andrew D Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on September 15, 2026 for $145.29 per share.
NASDAQ
Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on September 15, 2026.
NASDAQ
Andrew D Dickinson, Chief Financial Officer of Gilead Sciences, Inc., reported multiple transactions in common stock on September 10, 2026.
NASDAQ
Dietmar Berger, Chief Medical Officer of Gilead Sciences, Inc., reported multiple transactions in common stock on September 10, 2026.
NASDAQ
Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, Inc., reported multiple transactions in common stock on September 10, 2026.
NASDAQ
Wettan Keeley M Cain, EVP Gen Counsel, Legal & Comp of Gilead Sciences, Inc., reported multiple transactions in common stock on September 10, 2026.
NASDAQ
Daniel Patrick O'Day, Chairman & CEO and a Director of Gilead Sciences, Inc., reported multiple transactions in common stock on September 10, 2026.
NASDAQ
Form 4: Gilead Sciences CEO Sells Shares
Daniel Patrick O'Day, Chairman & CEO and a Director of Gilead Sciences, Inc., sold 15,000 shares of common stock on September 1, 2026.
NASDAQ
Anthony Welters, a Director of Gilead Sciences, Inc., sold 18,000 shares of common stock on August 26, 2026.
NASDAQ
Jeffrey Bluestone, a Director of Gilead Sciences, Inc., sold 5,000 shares of common stock on August 20, 2026.
NASDAQ
Form 4: Gilead Sciences CFO Sells Shares
Andrew D Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on August 17, 2026 for $138.36 per share.
NASDAQ
Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, Inc., sold 28,000 shares of common stock on August 17, 2026.
NASDAQ
Wettan Keeley M Cain, EVP Gen Counsel, Legal & Comp of Gilead Sciences, Inc., reported multiple transactions in common stock on August 10, 2026.
NASDAQ
Form 4: Gilead Sciences CEO Sells Shares
Daniel Patrick O'Day, Chairman & CEO and a Director of Gilead Sciences, Inc., sold 15,000 shares of common stock on August 3, 2026.
NASDAQ
Form 4: Gilead Sciences CFO Sells Shares
Andrew D Dickinson, Chief Financial Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on July 15, 2026 for $129.93 per share.
NASDAQ
Johanna Mercier, Chief Comm & Corp Aff Officer of Gilead Sciences, Inc., sold 3,000 shares of common stock on July 15, 2026 for $129.92 per share.
NASDAQ
Gilead Sciences Chairman & CEO Daniel O'Day reported the sale of company stock under a pre-arranged trading plan.
NASDAQ
Gilead Sciences Chief Commercial & Corporate Affairs Officer Johanna Mercier sold 3,000 shares of common stock via a 10b5-1 plan.
NASDAQ
Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.
NASDAQ
Chief Medical Officer Dietmar Berger acquired 533 shares of Gilead Sciences common stock through the vesting of restricted stock units.
NASDAQ
EVP and General Counsel Keeley M. Cain Wettan exercised restricted stock units and sold shares to cover tax obligations.
NASDAQ
Gilead Sciences CFO Andrew D. Dickinson acquired 2,796 shares via restricted stock unit vesting and disposed of 1,341 shares to cover tax obligations.
NASDAQ
Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, reported the vesting and sale of restricted stock units.
NASDAQ
Gilead Sciences Chairman and CEO Daniel O'Day acquired 8,779 shares through the vesting of restricted stock units.
NASDAQ
Gilead Sciences Chairman and CEO Daniel O'Day sold 15,000 shares of common stock under a pre-established Rule 10b5-1 trading plan.
NASDAQ
Gilead Sciences acquired 471,698 additional shares of Assembly Biosciences at $26.50 per share.
NASDAQ
Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
NASDAQ
Johanna Mercier, Chief Commercial & Corporate Affairs Officer at Gilead Sciences, exercised options and sold 28,000 shares under a 10b5-1 plan.
NASDAQ
Gilead Sciences Director Jeffrey Bluestone acquired 1,146 restricted stock units and 4,884 stock options on April 30, 2026.